Trinity Biotech
TRIB
45 hedge funds and large institutions have $57.2M invested in Trinity Biotech in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2% more funds holding
Funds holding: 44 → 45 (+1)
0% less ownership
Funds ownership: 0.1% → 0.1% (-0%)
22% less capital invested
Capital invested by funds: $72.9M → $57.2M (-$15.7M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$579K |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$213K |
| 3 |
ARM
Adirondack Research & Management
Guilderland,
New York
|
+$205K |
| 4 |
Renaissance Technologies
New York
|
+$180K |
| 5 |
VF
Virtu Financial
New York
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$707K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$437K |
| 3 |
D.E. Shaw & Co
New York
|
-$348K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$317K |
| 5 |
TA
Teton Advisors
Rye,
New York
|
-$314K |
TRIB Hedge Fund Activity: Q3 2018 in Review
45 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2018, worth a combined $57.2M — down 22% from $72.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRIB positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 15 trimmed.
The largest buyer was Stonehill Capital Management, adding an estimated $579K. The largest seller was Boston Partners, cutting an estimated $707K.
- 45 institutional investors held Trinity Biotech (TRIB) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $57.2M of Trinity Biotech stock for Q3 2018, down 22% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q3 2018 and 3 closed out, a net change of +1 holder.
- The largest Trinity Biotech buyer in Q3 2018 was Stonehill Capital Management, an estimated $579K added.
- The largest Trinity Biotech seller in Q3 2018 was Boston Partners, an estimated $707K sold.
Based on aggregated 13F filings for Q3 2018.